Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Sorry Mugsy

<< Previous

Bullboard Posts

Next >>

Post by woundedkneeon Apr 24, 2023 3:19pm

391 Views

Post# 35410988

Sorry Mugsy

You've fought the good fight. Time to cash out and move on. This company's success is light years away imo, and is just surviving on the cash it holds. I for one would have liked to see a revival and some kind of hope that management could fast track their plan, but this seems to be dead in the water. Again...jmo gl

<< Previous

Bullboard Posts

Next >>

Here are three global stocks you should watch